Skip to main content
Erschienen in: International Ophthalmology 7/2020

20.03.2020 | Original Paper

Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign

verfasst von: Vijitha S. Vempuluru, Saumya Jakati, Rashmi Krishnamurthy, Sirisha Senthil, Swathi Kaliki

Erschienen in: International Ophthalmology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To discuss the clinical presentation and management of intraocular tumors masquerading as primary glaucoma or non-tumor-related secondary glaucoma.

Methods

Retrospective chart review.

Results

Ten patients with unsuspected intraocular tumor were referred to glaucoma clinic with a diagnosis of primary glaucoma or non-tumor-related secondary glaucoma. The mean age at referral was 25 years (median, 22 years; range, 1 day to 58 years). Referral diagnosis included neovascular glaucoma (n = 6), congenital glaucoma (n = 3), and angle-closure glaucoma (n = 1). The significant clinical signs included corneal edema (n = 3), megalocornea (n = 3), iris neovascularization (n = 4), hyphema (n = 2), and pseudohypopyon (n = 2). The mean interval between the onset of symptoms and the establishment of accurate diagnosis was 4 months (median, 3 months; range, 0.5–13 months). Two patients underwent inadvertent trabeculectomy, and one patient underwent evisceration prior to definitive diagnosis. The final diagnosis included uveal melanocytoma (n = 2), ciliary body medulloepithelioma (n = 2), choroidal melanoma (n = 2), retinoblastoma (n = 1), retinal capillary hemangioblastoma (n = 1), choroidal schwannoma (n = 1), and uveal metastasis (n = 1). The treatment modalities included plaque radiotherapy (n = 1), enucleation (n = 6), palliative systemic chemotherapy (n = 1), a combination of enucleation, systemic chemotherapy, and external beam radiotherapy (n = 1), and one patient was lost to follow-up. There was no evidence of death over a mean follow-up period of 13 months (median, 5 months; range, 2 weeks to 7 years).

Conclusion

Unilateral raised intraocular pressure, iris neovascularization, or both may be the presenting features of intraocular tumors. High degree of suspicion and a thorough examination reveals the definitive diagnosis.
Literatur
1.
Zurück zum Zitat Shields CL, Shields JA, Shields MB, Augsburger JJ (1987) Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 94(7):839–846CrossRef Shields CL, Shields JA, Shields MB, Augsburger JJ (1987) Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 94(7):839–846CrossRef
2.
Zurück zum Zitat Yang M, Wang W, Yan JH et al (2015) Eye tumors misdiagnosed as glaucoma. Chin Med J 128:273–276CrossRef Yang M, Wang W, Yan JH et al (2015) Eye tumors misdiagnosed as glaucoma. Chin Med J 128:273–276CrossRef
3.
Zurück zum Zitat Marchini G, Toscani M, Chemello F (2014) Pediatric glaucoma: current perspectives. Pediatr Health Med Ther 5:15–27CrossRef Marchini G, Toscani M, Chemello F (2014) Pediatric glaucoma: current perspectives. Pediatr Health Med Ther 5:15–27CrossRef
4.
Zurück zum Zitat Kaliki S, Jajapuram SD (2019) Neonatal retinoblastoma: a study of five cases. Oman J Ophthalmol 12:156–159CrossRef Kaliki S, Jajapuram SD (2019) Neonatal retinoblastoma: a study of five cases. Oman J Ophthalmol 12:156–159CrossRef
5.
Zurück zum Zitat Etienne R, Etienne R (1972) Unilateral glaucoma. Br J Ophthalmol 56(3):254–258CrossRef Etienne R, Etienne R (1972) Unilateral glaucoma. Br J Ophthalmol 56(3):254–258CrossRef
6.
Zurück zum Zitat Miles DR, Boniuk M (1966) Pathogenesis of unilateral glaucoma. A review of 100 cases. Am J Ophthalmol 62(3):493–499CrossRef Miles DR, Boniuk M (1966) Pathogenesis of unilateral glaucoma. A review of 100 cases. Am J Ophthalmol 62(3):493–499CrossRef
7.
Zurück zum Zitat Teekhasaenee C, Ritch R, Rutnin U, Leelawongs N (1990) Glaucoma in oculodermal melanocytosis. Ophthalmology 97(5):562–570CrossRef Teekhasaenee C, Ritch R, Rutnin U, Leelawongs N (1990) Glaucoma in oculodermal melanocytosis. Ophthalmology 97(5):562–570CrossRef
8.
Zurück zum Zitat Bajaj MS, Khuraijam N, Sen S, Pushker N (2009) Congenital melanocytoma manifesting as proptosis with multiple cutaneous melanocytic nevi and oculodermal melanosis. Arch Ophthalmol 127(7):936–945CrossRef Bajaj MS, Khuraijam N, Sen S, Pushker N (2009) Congenital melanocytoma manifesting as proptosis with multiple cutaneous melanocytic nevi and oculodermal melanosis. Arch Ophthalmol 127(7):936–945CrossRef
9.
Zurück zum Zitat Kassa E, Li H, Sun Y (2014) Neovascular glaucoma in a child: an unusual presentation of medulloepithelioma. GMS Ophthalmol Cases 17:4 Kassa E, Li H, Sun Y (2014) Neovascular glaucoma in a child: an unusual presentation of medulloepithelioma. GMS Ophthalmol Cases 17:4
10.
Zurück zum Zitat Othman IS, Assem M, Zaki IMA (2013) Secondary glaucoma as initial manifestation of uveal melanoma. Saudi J Ophthalmol 23:203–208CrossRef Othman IS, Assem M, Zaki IMA (2013) Secondary glaucoma as initial manifestation of uveal melanoma. Saudi J Ophthalmol 23:203–208CrossRef
11.
Zurück zum Zitat Sahu S, Bhutia TW, Shrestha V, Singh SK, Puri LR (2019) Large choroidal melanoma presenting as neovascular glaucoma. GMS Ophthalmol Cases 9:Doc19PubMedPubMedCentral Sahu S, Bhutia TW, Shrestha V, Singh SK, Puri LR (2019) Large choroidal melanoma presenting as neovascular glaucoma. GMS Ophthalmol Cases 9:Doc19PubMedPubMedCentral
12.
Zurück zum Zitat Camp DA, Yadav P, Dalvin LA, Shields CL (2019) Glaucoma secondary to intraocular tumors: mechanisms and management. Curr Opin Ophthalmol 30(2):71–81CrossRef Camp DA, Yadav P, Dalvin LA, Shields CL (2019) Glaucoma secondary to intraocular tumors: mechanisms and management. Curr Opin Ophthalmol 30(2):71–81CrossRef
13.
Zurück zum Zitat Yanoff M (1970) Glaucoma mechanisms in ocular malignant melanoma. Am J Ophthalmol 70:898–904CrossRef Yanoff M (1970) Glaucoma mechanisms in ocular malignant melanoma. Am J Ophthalmol 70:898–904CrossRef
14.
Zurück zum Zitat Bhorade AM, Edward DP, Goldstein DA (1999) Ciliary body melanocytoma with anterior segment pigment dispersion and elevated intraocular pressure. J Glaucoma 8(2):129–133CrossRef Bhorade AM, Edward DP, Goldstein DA (1999) Ciliary body melanocytoma with anterior segment pigment dispersion and elevated intraocular pressure. J Glaucoma 8(2):129–133CrossRef
15.
Zurück zum Zitat Jajapuram SD, Mishra DK, Kaliki S (2019) Choroidal schwannoma presenting with neovascular glaucoma: a report of two cases. Oman J Ophthalmol 12(2):125–128CrossRef Jajapuram SD, Mishra DK, Kaliki S (2019) Choroidal schwannoma presenting with neovascular glaucoma: a report of two cases. Oman J Ophthalmol 12(2):125–128CrossRef
16.
Zurück zum Zitat Kaliki S, Eagle RC, Grossniklaus HE, Campbell RJ, Shields CL, Shields JA (2013) Inadvertent implantation of aqueous tube shunts in glaucomatous eyes with unrecognized intraocular neoplasms: report of 5 cases. JAMA Ophthalmol 131(7):925–928CrossRef Kaliki S, Eagle RC, Grossniklaus HE, Campbell RJ, Shields CL, Shields JA (2013) Inadvertent implantation of aqueous tube shunts in glaucomatous eyes with unrecognized intraocular neoplasms: report of 5 cases. JAMA Ophthalmol 131(7):925–928CrossRef
17.
Zurück zum Zitat Kaliki S, Shields CL, Eagle RC Jr et al (2013) Ciliary body medulloepithelioma: analysis of 41 cases. Ophthalmology 120(12):2552–2559CrossRef Kaliki S, Shields CL, Eagle RC Jr et al (2013) Ciliary body medulloepithelioma: analysis of 41 cases. Ophthalmology 120(12):2552–2559CrossRef
Metadaten
Titel
Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign
verfasst von
Vijitha S. Vempuluru
Saumya Jakati
Rashmi Krishnamurthy
Sirisha Senthil
Swathi Kaliki
Publikationsdatum
20.03.2020
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 7/2020
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-020-01348-x

Weitere Artikel der Ausgabe 7/2020

International Ophthalmology 7/2020 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.